Price T Rowe Associates Inc Atea Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 66,660 shares of AVIR stock, worth $238,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,660
Previous 67,137
0.71%
Holding current value
$238,642
Previous $272,000
18.75%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding AVIR
# of Institutions
110Shares Held
51.5MCall Options Held
71.8KPut Options Held
318K-
Black Rock Inc. New York, NY9.12MShares$32.7 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$23.8 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$19.5 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$16.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.48MShares$16 Million1.81% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $298M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...